Q&A with John Bothmer, Clinical Translation Medicine Fellow at Angelini Pharma To further explore the scientific, regulatory and operational complexity behind FirstinHuman trials , we spoke with John Bothmer, Clinical Translation Medicine Fellow within the Global Clinical Development & Clinical Operations department at Angelini Pharma , about the role these studies play in clinical development and the safeguards that support this transition from preclinical research to human investigation
Our approach includes: Licensed clinician oversight
804443) and 100 g/mL streptomycin (Reig Jofre S.A., Madrid, Spain
8 weeks (8 total vials): 16 mL 2 10 mL bottles 12 weeks (11 total vials): 22 mL 3 10 mL bottles 16 weeks (13 total vials): 26 mL 3 10 mL bottles Alcohol Swabs: One for the vial stopper + one for the injection site each administration
PSPeptides meets all of the above standards for research-grade supply: third-party HPLC purity testing at 99%+, MS confirmation of molecular weight, US-based synthesis, and same-day shipping with full CoA documentation included
BPC 157 has shown significant promise in treating various conditions, including neurological recovery and wound healing, due to its robust cytoprotective properties
)
